Compare MCI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | VNDA |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.8M | 474.0M |
| IPO Year | N/A | 2006 |
| Metric | MCI | VNDA |
|---|---|---|
| Price | $20.50 | $7.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 40.4K | ★ 932.1K |
| Earning Date | 01-01-0001 | 02-11-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $24.28 |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $12.96 | $3.81 |
| 52 Week High | $19.24 | $9.60 |
| Indicator | MCI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 50.35 |
| Support Level | $20.19 | $7.22 |
| Resistance Level | $21.05 | $8.30 |
| Average True Range (ATR) | 0.52 | 0.42 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 50.15 | 33.51 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.